Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia

Leukemia

Volumn 29, Issue 9, 2015, Pages 1799-1810

  Parrish, C ^a   Scott, G B ^a   Migneco, G ^a   Scott, K J ^a   Steele, L P ^a   Ilett, E ^a   West, E J ^a   Hall, K ^a   Selby, P J ^a   Buchanan, D ^a   Varghese, A ^a   Cragg, M S ^b   Coffey, M ^c   Hillmen, P ^d   Melcher, A A ^a   Errington Mais, F ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c ONCOLYTICS BIOTECH INC   (Canada)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; CD20 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUDARABINE; OBINUTUZUMAB; OFATUMUMAB; PELAREOREP; RITUXIMAB; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; ONCOLYTIC VIRUS;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG CYTOTOXICITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; MAMMALIAN ORTHOREOVIRUS 3; MONOCYTE; MONOTHERAPY; NATURAL KILLER CELL; ONCOLYTIC VIROTHERAPY; PHENOTYPE; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS ACTIVATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; CANCER STAGING; CYTOPATHOGENIC EFFECT; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INNATE IMMUNITY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; MIDDLE AGED; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; MALE; MAMMALIAN ORTHOREOVIRUS 3; MIDDLE AGED; NEOPLASM STAGING; ONCOLYTIC VIRUSES; RITUXIMAB; VIRUS REPLICATION;

EID: 84940790165     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.88     Document Type: Article

References (62)

1. Palmer S, Hanson CA, Zent CS, Porrata LF, Laplant B, Geyer SM et al. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematology 2008; 141: 607-614.
2. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010; 95: 135-143.
3. Nabhan C, Coutre S, Hillmen P. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime? Br J Haematol 2007; 136: 379-392.
4. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014; 370: 2286-2294.
5. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44: 3823-3837.
6. Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M et al. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol 2013; 190: 2702-2711.
7. Riaz W, Hernandez-Ilizaliturri FJ, Czuczman MS. Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. Immunol Res 2010; 46: 192-205.
8. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008; 14: 4650-4657.
9. Bologna L, Gotti E, Da Roit F, Intermesoli T, Rambaldi A, Introna M et al. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol 2013; 190: 231-239.
10. Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186: 3762-3769.
11. Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 2010; 21: 91-98.
12. Donnelly OG, Errington-Mais F, Prestwich R, Harrington K, Pandha H, Vile R et al. Recent clinical experience with oncolytic viruses. Curr Pharm Biotechnol 2012; 13: 1834-1841.
13. Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, Auer Y et al. Reovirus therapy of lymphoid malignancies. Blood 2002; 100: 4146-4153.
14. Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Gao H, Bahlis N et al. Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clin Cancer Res 2012; 18: 4962-4972.
15. Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Bahlis N, Neri P et al. Reovirus as a successful ex vivo purging modality for multiple myeloma. Bone Marrow Transplant 2014; 49: 80-86.
16. Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther 2008; 8: 1581-1588.
17. Adair RA, Scott KJ, Fraser S, Errington-Mais F, Pandha H, Coffey M et al. Cytotoxic and immune-mediated killing of human colorectal cancer by reovirusloaded blood and liver mononuclear cells. Int J Cancer 2013; 132: 2327-2338.
18. El-Sherbiny YM, Holmes TD, Wetherill LF, Black EV, Wilson EB, Phillips SL et al. Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo. Clin Exp Immunol 2014; 180: 98-107.
19. Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984; 63: 305-309.
20. Buechele C, Baessler T, Schmiedel BJ, Schumacher CE, Grosse-Hovest L, Rittig K et al. 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia. Eur J Immunol 2012; 42: 737-748.
21. Willmore E, Elliott SL, Mainou-Fowler T, Summerfield GP, Jackson GH, O'Neill F et al. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008; 14: 3984-3992.
22. Vaughan AT, Iriyama C, Beers SA, Chan CH, Lim SH, Williams EL et al. Inhibitory FcgammaRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood 2014; 123: 669-677.
23. Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Therapy 2008; 15: 1257-1270.
24. Prestwich RJ, Errington F, Steele LP, Ilett EJ, Morgan RS, Harrington KJ et al. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol 2009; 183: 4312-4321.
25. Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008; 180: 6018-6026.
26. Pascutti MF, Jak M, Tromp JM, Derks IA, Remmerswaal EB, Thijssen R et al. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood 2013; 122: 3010-3019.
27. Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 2008; 14: 7358-7366.
28. Du J, Lopez-Verges S, Pitcher BN, Johnson J, Jung SH, Zhou L et al. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2014; 2: 878-889.
29. Hansmann L, Groeger S, von Wulffen W, Bein G, Hackstein H. Human monocytes represent a competitive source of interferon-alpha in peripheral blood. Clin Immunol 2008; 127: 252-264.
30. Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 2013; 12: 2031-2042.
31. Thirukkumaran CM, Luider JM, Stewart DA, Cheng T, Lupichuk SM, Nodwell MJ et al. Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood 2003; 102: 377-387.
32. Tumilasci VF, Oliere S, Nguyen TL, Shamy A, Bell J, Hiscott J. Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol 2008; 82: 8487-8499.
33. Samuel S, Tumilasci VF, Oliere S, Nguyen TL, Shamy A, Bell J et al. VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia. Mol Ther 2010; 18: 2094-2103.
34. Kim MK, Breitbach CJ, Moon A, Heo J, Lee YKCho M et al. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Transl Med 2013; 5: 185ra63.
35. Ziegler HW, Kay NE, Zarling JM. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981; 27: 321-327.
36. Veuillen C, Aurran-Schleinitz T, Castellano R, Rey J, Mallet F, Orlanducci F et al. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol 2012; 32: 632-646.
37. Kay NE, Zarling J. Restoration of impaired natural killer cell activity of B-chronic lymphocytic leukemia patients by recombinant interleukin-2. Am J Hematol 1987; 24: 161-167.
38. Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc 2014; 89: 926-933.
39. Todo T. Active immunotherapy: oncolytic virus therapy using HSV-1. Adv Exp Med Biol 2012; 746: 178-186.
40. Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 2009; 15: 4374-4381.
41. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010; 17: 718-730.
42. Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 2010; 16: 3067-3077.
43. Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, Fuller M et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med 2012; 4: 138ra177.
44. Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ et al. Phase II trial of intravenous administration of Reolysin((R)) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther 2012; 20: 1998-2003.
45. Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski GB, Benson DM Jr, et al. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clin Cancer Res 2014; 20: 5946-5955.
46. Roulstone V, Khan K, Pandha HS, Rudman S, Coffey M, Gill GM et al. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Clin Cancer Res 2014; 21: 1305-1312.
47. Ilett E, Kottke T, Donnelly O, Thompson J, Willmon C, Diaz R et al. Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus. Mol Ther 2014; 22: 1851-1863.
48. Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 2012; 18: 2080-2089.
49. Pangalis GA, Griva E. Recombinant alfa-2b-interferon therapy in untreated, stages A and B chronic lymphocytic leukemia. A preliminary report. Cancer 1988; 61: 869-872.
50. Ziegler-Heitbrock HW, Schlag R, Flieger D, Thiel E. Favorable response of early stage B CLL patients to treatment with IFN-alpha 2. Blood 1989; 73: 1426-1430.
51. Buggins AG, Patten PE, Richards J, Thomas NS, Mufti GJ, Devereux S. Tumorderived IL-6 may contribute to the immunological defect in CLL. Leukemia 2008; 22: 1084-1087.
52. Lotz M, Ranheim E, Kipps TJ. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med 1994; 179: 999-1004.
53. Meadows SK, Eriksson M, Barber A, Sentman CL. Human NK cell IFN-gamma production is regulated by endogenous TGF-beta. Int Immunopharmacol 2006; 6: 1020-1028.
54. Grzywnowicz M, Zaleska J, Mertens D, Tomczak W, Wlasiuk P, Kosior K et al. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One 2012; 7: e35178.
55. Voso MT, Pantel G, Rutella S, Weis M, D'Alo F, Urbano R et al. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica 2002; 87: 918-925.
56. Lefebvre ML, Krause SW, Salcedo M, Nardin A. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother 2006; 29: 388-397.
57. Nakagawa T, Natsume A, Satoh M, Niwa R. Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcgammaRIIIb on neutrophils. Leukemia Res 2010; 34: 666-671.
58. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111: 5291-5297.
59. James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol 2014; 32: 2067-2073.
60. Chanan-Khan A, Porter CW. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol 2006; 7: 480-488.
61. Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 2014; 123: 1957-1960.
62. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008; 14: 7127-7137.